<DOC>
	<DOCNO>NCT00281879</DOCNO>
	<brief_summary>RATIONALE : A peripheral stem cell transplant umbilical cord blood transplant donor may able replace blood-forming cell destroy chemotherapy radiation therapy . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) transplant may help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell make immune response body 's normal cell . Methotrexate , cyclosporine , tacrolimus , methylprednisolone may stop happen . PURPOSE : This clinical trial study well donor stem cell transplant donor white blood cell infusion work treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Donor White Blood Cell Infusions Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effectiveness unrelated donor allogeneic hematopoietic stem cell transplantation condition treatment patient high-risk hematologic malignancy . - Compare survival , disease-free survival ( DFS ) , response rate , toxicity rate patient historical control . - Compare rate severity acute chronic GVHD allogeneic hematopoietic stem cell transplantation patient hematopoietic malignancy historical control transplant stem cell related sibling donor - Assess engraftment , long-term hematopoietic recovery , relapse rate , disease-free survival allogeneic hematopoietic stem cell use source stem cell transplantation patient high-risk hematological malignancy . - Assess engraftment , long-term hematopoietic recovery , overall survival allogeneic hematopoietic stem cell use source stem cell transplantation patient graft failure graft rejection . - Compare engraftment , long-term hematopoietic recovery , rate GVHD , rate relapse , toxicity rate , overall disease-free survival overall survival donor leukocyte infusion ( DLI ) give patient disease recurrence , progression , low donor chimerisms unrelated stem cell transplantation DLI historical control donor leukocyte infusion . Secondary - Determine quality life patient undergoing hematopoietic stem cell transplantation donor leukocyte infusion unrelated HLA genotypically-identical donor . OUTLINE : Patients assign 1 8 treatment group . - Group 1* : Patients undergo total body irradiation ( TBI ) twice day day -7 -4 . Patients receive cyclophosphamide IV 1 hour day -3 -2 . On day 0 patient undergo stem cell transplantation ( SCT ) . Beginning day 7 , patient receive filgrastim ( G-CSF ) IV daily blood count recover . - Group 2 ( patient previously experience dose-limiting radiotherapy ) : Patients receive oral busulfan 4 time daily day -7 -4 cyclophosphamide IV 1 hour day -3 -2 . On day 0 patient undergo SCT . Beginning day 7 , patient receive G-CSF IV daily blood count recover . - Group 3 ( pediatric patient ) : Patients receive busulfan IV 4 time daily day -9 -6 cyclophosphamide IV 1 hour fludarabine IV 30 minute day -5 -2 . On day 0 patient undergo SCT . Beginning day 7 , patient may receive G-CSF IV daily blood count recover . - Group 4 ( second SCT patient experience graft rejection failure ) * : Patients receive low-dose fludarabine IV 30 minute day -4 -2 . Patients undergo low-dose TBI follow SCT day 0 . Beginning day 7 , patient may receive G-CSF IV daily blood count recover . - Group 5 ( patient develop grade 3 cystitis prior cyclophosphamide-containing therapy ) : Patients receive carmustine IV 2 hour day -6 , etoposide IV 2 hour cytarabine IV 30 minute day -5 -2 , melphalan IV 30 minute day -1 ( BEAM ) . On day 0 , patient undergo SCT . Beginning day 7 , patient receive G-CSF IV daily blood count recover . - Group 6 ( cord blood transplantation ) : Patients receive anti-thymocyte globulin IV daily methylprednisolone IV twice daily day -3 -1 . On day 0 , patient undergo umbilical cord blood SCT . - Group 7 ( patient relapse progressive disease prior transplant low donor chimerisms ) * : Patients must exist graft-versus-host disease ( GVHD ) . Patients receive donor lymphocyte infusion condition chemotherapy and/or radiotherapy discretion investigator . - Group 8 ( pediatric patient ) * : Patients undergo TBI twice day day -7 -5 . Patients also receive etoposide IV 24 hour day -4 cyclophosphamide IV 1 hour day -3 -2 . On day 0 , patient undergo SCT . Beginning day 7 , patient may receive G-CSF IV daily blood count recover . NOTE : *Patients receive &gt; 3000 cGy central nervous system &gt; 2000 cGy lung liver may receive regimen contain total body irradiation ( TBI ) All patient receive GVHD prophylaxis comprise methotrexate IV day 1 , 3 , 6 , 11 ; cyclosporine and/or tacrolimus day -2 100 ; and/or methylprednisolone IV day 7 100 . Patients unrelated donor experience relapse prior transplantation , may proceed directly transplantation . However , immediate transplantation unrelated donor possible , patient must re-induced complete hematological remission . Patients experience graft failure graft rejection allogeneic transplantation eligible second stem cell infusion original donor . Quality life assess baseline 7 day , 3 month , 1 year transplantation . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 43 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following* : Acute lymphoblastic leukemia disease phase Patients follow highrisk feature encourage enroll : Philadelphia chromosome positive disease L3 morphology , especially presence ( 8 ; 14 ) , ( 8 ; 22 ) , ( 2 ; 8 ) Patients remission day 28 first induction High LDH ( i.e. , ≥ 300 IU/mL presentation ) PreBcell , mixed lineage , Burkitt 's marker Relapsed marrow receive continuous chemotherapy Within 6 month stop chemotherapy Relapse one organ extramedullary relapse one organ still receive chemotherapy Hodgkin 's nonHodgkin 's lymphoma beyond first complete remission ( CR ) first CR feature highrisk disease , include , limited : Lymphoma CR 3 course primary therapy Patients bulky disease presentation , especially bulky mediastinal disease Patients LDH ≥ 300 IU/mL presentation Patients extranodal disease Patients first remission within less 1 year Stage IV disease presentation , especially marrow involvement Patients highintermediate high International Index Scores Acute myeloid leukemia ( AML ) meeting follow criterion : Beyond first remission highrisk disease first CR Required multiple course induction therapy achieve remission Had residual leukemia day 1428 bone marrow examination initial induction Patients cytogenetic abnormality except inv 16 ( 8 ; 21 ) Chronic myelogenous leukemia chronic early accelerate phase disease Patients blast crisis induce back chronic phase may transplant second chronic phase Myelodysplastic syndrome ( MDS ) meeting follow requirement : Transfusiondependent refractory anemia ( RA ) , RA excess blast ( RAEB ) , RAEB transformation , chronic myelomonocytic leukemia ( CMML ) Patients MDS present evolve AML must reinduced back remission prior initiate search unrelated donor NOTE : *Patients hematologic malignancy list , include disease chronic lymphocytic leukemia ( CLL ) , multiple myeloma , rare pediatric malignancy , patient felt highrisk relapse feature list , may allow discretion investigator . Must fail prior stem cell transplantation Must suitable unrelated allogeneic hematopoietic stem cell donor A 5/6 match degree acceptable unrelated bone marrow donors A 4/6 match degree acceptable unrelated cord blood unit PATIENT CHARACTERISTICS : SWOG performance status ( PS ) 02 OR Karnofsky PS 50100 % OR Lansky PS 50100 % Creatinine clearance ≥ 45 mL/min Creatinine ≤ 2.5 mg/dL Bilirubin ≤ 2 mg/dL ( abnormally high liver function test allow source elevation due lymphoma liver ) AST ALT ≤ 2 time normal ( abnormally high liver function test allow source elevation due lymphoma liver ) No patient high risk venoocclusive disease Not pregnant nursing Negative serum pregnancy test Fertile patient must use effective contraceptive method DLCO ≥ 50 % predict FEV_1/FVC ≥ 65 % predict No current congestive heart failure ( CHF ) and/or LVEF ≥ 45 % No myocardial infarction within past 6 month No unstable angina within past 6 month HIV negative Life expectancy must limit disease malignancy No allergy chemotherapeutic agent include regimen PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>unusual cancer childhood</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>